# CEB-01 in Locally Resectable Pancreatic Cancer

> **NCT06538857** · PHASE2 · RECRUITING · sponsor: **CEBIOTEX** · enrollment: 39 (estimated)

## Conditions studied

- Pancreatic Carcinoma

## Interventions

- **PROCEDURE:** Standard surgery
- **DRUG:** CEB-01

## Key facts

- **NCT ID:** NCT06538857
- **Lead sponsor:** CEBIOTEX
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2025-05-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06538857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06538857, "CEB-01 in Locally Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT06538857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*